Perseus Proteomics (4882.T) Stock Price

Perseus Proteomics Price

CLOSED
147.00JPY+4.00 (+2.76 %)
Market closed

Revenue at Perseus Proteomics has contracted by 12.4% per year over the past 7 years to 120.38 M JPY. For Perseus Proteomics, the net margin of -751.7% is down versus -608.1% a few years ago. The consensus 12-month price target for Perseus Proteomics is 765.00 JPY, about 420.4% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 7% above its 52-week low.

Perseus Proteomics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Perseus Proteomics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Perseus Proteomics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Perseus Proteomics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Perseus Proteomics Stock Price History
DatePerseus Proteomics Price
8/13/2026147.00 JPY
8/12/2026143.00 JPY
8/10/2026143.00 JPY
8/7/2026142.00 JPY
8/6/2026142.00 JPY
8/5/2026142.00 JPY
8/4/2026142.00 JPY
8/3/2026137.00 JPY
7/31/2026146.00 JPY
7/30/2026143.00 JPY
7/29/2026143.00 JPY
7/28/2026145.00 JPY
7/27/2026149.00 JPY
7/24/2026143.00 JPY
7/23/2026148.00 JPY
7/22/2026148.00 JPY
7/21/2026148.00 JPY
7/17/2026149.00 JPY
7/16/2026158.00 JPY
7/15/2026160.00 JPY
7/14/2026156.00 JPY
7/13/2026155.00 JPY
7/10/2026158.00 JPY
7/9/2026150.00 JPY
7/8/2026149.00 JPY
7/7/2026155.00 JPY
7/6/2026159.00 JPY
7/3/2026152.00 JPY
7/2/2026156.00 JPY
7/1/2026164.00 JPY
6/30/2026159.00 JPY
6/29/2026163.00 JPY
6/26/2026164.00 JPY
6/25/2026170.00 JPY
6/24/2026158.00 JPY
6/23/2026144.00 JPY
6/22/2026152.00 JPY
6/19/2026147.00 JPY
6/18/2026151.00 JPY
6/17/2026145.00 JPY
6/16/2026145.00 JPY
6/15/2026143.00 JPY
6/12/2026146.00 JPY
6/11/2026150.00 JPY
6/10/2026146.00 JPY
6/9/2026150.00 JPY
6/8/2026148.00 JPY
6/5/2026151.00 JPY
6/4/2026148.00 JPY
6/3/2026151.00 JPY
6/2/2026152.00 JPY
6/1/2026153.00 JPY
5/29/2026155.00 JPY
5/28/2026161.00 JPY
5/27/2026164.00 JPY
5/26/2026166.00 JPY
5/25/2026164.00 JPY
5/22/2026171.00 JPY
5/21/2026171.00 JPY
5/20/2026170.00 JPY
5/19/2026175.00 JPY
5/18/2026174.00 JPY
5/15/2026180.00 JPY
5/14/2026189.00 JPY
5/13/2026191.00 JPY
5/12/2026205.00 JPY
5/11/2026214.00 JPY
5/8/2026217.00 JPY
5/7/2026213.00 JPY
5/1/2026215.00 JPY
4/30/2026214.00 JPY
4/28/2026218.00 JPY
4/27/2026215.00 JPY
4/24/2026217.00 JPY
4/23/2026221.00 JPY
4/22/2026226.00 JPY
4/21/2026227.00 JPY
4/20/2026232.00 JPY
4/17/2026232.00 JPY
4/16/2026238.00 JPY
4/15/2026241.00 JPY
4/14/2026233.00 JPY
4/13/2026236.00 JPY
4/10/2026243.00 JPY
4/9/2026245.00 JPY
4/8/2026253.00 JPY
4/7/2026237.00 JPY
4/6/2026226.00 JPY
4/3/2026220.00 JPY
4/2/2026219.00 JPY
4/1/2026228.00 JPY
3/31/2026220.00 JPY
3/30/2026223.00 JPY
3/27/2026242.00 JPY
3/26/2026216.00 JPY
3/25/2026227.00 JPY
3/24/2026215.00 JPY
3/23/2026211.00 JPY
3/19/2026224.00 JPY
3/18/2026229.00 JPY
3/17/2026234.00 JPY
3/16/2026253.00 JPY
3/13/2026258.00 JPY
3/12/2026277.00 JPY
3/11/2026277.00 JPY
3/10/2026293.00 JPY
3/9/2026288.00 JPY
3/6/2026233.00 JPY
3/5/2026229.00 JPY
3/4/2026208.00 JPY
3/3/2026224.00 JPY
3/2/2026231.00 JPY
2/27/2026234.00 JPY
2/26/2026227.00 JPY
2/25/2026225.00 JPY
2/24/2026225.00 JPY
2/20/2026232.00 JPY
2/19/2026237.00 JPY
2/18/2026241.00 JPY
2/17/2026232.00 JPY
2/16/2026230.00 JPY
2/13/2026229.00 JPY
2/12/2026236.00 JPY
2/10/2026238.00 JPY
2/9/2026238.00 JPY
2/6/2026238.00 JPY
2/5/2026245.00 JPY
2/4/2026240.00 JPY
2/3/2026241.00 JPY
2/2/2026237.00 JPY
1/30/2026240.00 JPY
1/29/2026236.00 JPY
1/28/2026239.00 JPY
1/27/2026244.00 JPY
1/26/2026248.00 JPY
1/23/2026255.00 JPY
1/22/2026255.00 JPY
1/21/2026254.00 JPY
1/20/2026262.00 JPY
1/19/2026262.00 JPY
1/16/2026273.00 JPY
1/15/2026256.00 JPY
1/14/2026248.00 JPY
1/13/2026236.00 JPY
1/9/2026230.00 JPY
1/8/2026237.00 JPY
1/7/2026228.00 JPY
1/6/2026228.00 JPY
1/5/2026228.00 JPY
12/30/2025224.00 JPY
12/29/2025220.00 JPY
12/26/2025220.00 JPY
12/25/2025222.00 JPY
12/24/2025220.00 JPY
12/23/2025208.00 JPY
12/22/2025205.00 JPY
12/19/2025215.00 JPY
12/18/2025216.00 JPY
12/17/2025265.00 JPY
12/16/2025277.00 JPY
12/15/2025288.00 JPY
12/12/2025288.00 JPY
12/11/2025296.00 JPY
12/10/2025309.00 JPY
12/9/2025287.00 JPY
12/8/2025286.00 JPY
12/5/2025292.00 JPY
12/4/2025295.00 JPY
12/3/2025293.00 JPY
12/2/2025300.00 JPY
12/1/2025304.00 JPY
11/28/2025312.00 JPY
11/27/2025300.00 JPY
11/26/2025299.00 JPY
11/25/2025295.00 JPY
11/21/2025295.00 JPY
11/20/2025307.00 JPY
11/19/2025297.00 JPY
11/18/2025299.00 JPY
11/17/2025299.00 JPY
11/14/2025303.00 JPY
11/13/2025311.00 JPY
11/12/2025311.00 JPY
11/11/2025303.00 JPY
11/10/2025290.00 JPY
11/7/2025291.00 JPY
11/6/2025296.00 JPY
11/5/2025294.00 JPY
11/4/2025296.00 JPY
10/31/2025291.00 JPY
10/30/2025294.00 JPY
10/29/2025285.00 JPY
10/28/2025297.00 JPY
10/27/2025302.00 JPY
10/24/2025299.00 JPY
10/23/2025304.00 JPY
10/22/2025310.00 JPY
10/21/2025309.00 JPY
10/20/2025309.00 JPY
10/17/2025304.00 JPY
10/16/2025310.00 JPY
10/15/2025321.00 JPY
10/14/2025308.00 JPY
10/10/2025325.00 JPY
10/9/2025321.00 JPY
10/8/2025316.00 JPY
10/7/2025315.00 JPY
10/6/2025313.00 JPY
10/3/2025313.00 JPY
10/2/2025310.00 JPY
10/1/2025309.00 JPY
9/30/2025320.00 JPY
9/29/2025326.00 JPY
9/26/2025320.00 JPY
9/25/2025331.00 JPY
9/24/2025335.00 JPY
9/22/2025342.00 JPY
9/19/2025343.00 JPY
9/18/2025345.00 JPY
9/17/2025351.00 JPY
9/16/2025353.00 JPY
9/12/2025339.00 JPY
9/11/2025343.00 JPY
9/10/2025346.00 JPY
9/9/2025341.00 JPY
9/8/2025354.00 JPY
9/5/2025357.00 JPY
9/4/2025355.00 JPY
9/3/2025354.00 JPY
9/2/2025358.00 JPY
9/1/2025347.00 JPY
8/29/2025344.00 JPY
8/28/2025343.00 JPY
8/27/2025342.00 JPY
8/26/2025343.00 JPY
8/25/2025339.00 JPY
8/22/2025342.00 JPY
8/21/2025343.00 JPY
8/20/2025354.00 JPY
8/19/2025367.00 JPY
8/18/2025369.00 JPY
Access this data via the Eulerpool API
Get Free API Key

Perseus Proteomics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
94.20 M JPY
-697.77 M JPY
-787.00 M JPY
Jan 1, 2024
100.40 M JPY
-894.73 M JPY
-1.10 B JPY
Jan 1, 2025
120.38 M JPY
-826.43 M JPY
-904.80 M JPY
Jan 1, 2026 (e)
1.32 B JPY
-1.32 B JPY
384.20 M JPY
Jan 1, 2027 (e)
120.00 M JPY
-120.00 M JPY
-1.06 B JPY
Jan 1, 2028 (e)
887.00 M JPY
-887.00 M JPY
-226.10 M JPY
Jan 1, 2029 (e)
150.00 M JPY
-150.00 M JPY
0.00 JPY
Jan 1, 2030 (e)
161.00 M JPY
-161.00 M JPY
0.00 JPY

Perseus Proteomics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 16, 2026, 9:13 AM
 
REVENUEB JPY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB JPY
EBITB JPY
EBIT MARGIN%
NET INCOMEB JPY
NET INCOME GROWTH%
SHARESM
201820192020202120222023202420252026e2027e2028e2029e2030e
0.300.280.090.070.070.090.100.121.320.120.890.150.16
–-9.24-69.09-21.185.9732.396.3820.00995.83-90.87639.17-83.097.33
29.7093.0992.9495.5294.3791.4987.0086.6786.6786.6786.6786.6786.67
0.090.260.080.060.070.090.090.101.140.100.770.130.14
-0.17-0.14-0.81-0.41-0.47-0.70-0.89-0.83-1.32-0.12-0.89-0.15-0.16
-54.79-52.36-955.29-613.43-664.79-741.49-894.00-688.33-100.00-100.00-100.00-100.00-100.00
-0.18-0.16-0.84-0.41-0.60-0.79-1.10-0.900.38-1.06-0.23––
–-8.43415.95-50.8945.0431.2240.46-18.12-142.48-376.56-78.72––
11.6911.6911.6911.6911.7611.7611.7914.2714.2714.2714.2714.2714.27
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Perseus Proteomics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Perseus Proteomics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Perseus Proteomics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Perseus Proteomics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Perseus Proteomics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Perseus Proteomics stock margins

The Perseus Proteomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Perseus Proteomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Perseus Proteomics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
94.34 %
-605.99 %
-608.14 %
Jan 1, 2022
94.18 %
-656.45 %
-832.76 %
Jan 1, 2023
91.86 %
-740.72 %
-835.45 %
Jan 1, 2024
87.33 %
-891.15 %
-1,100.04 %
Jan 1, 2025
86.44 %
-686.55 %
-751.65 %
Jan 1, 2026 (e)
86.44 %
-100.00 %
29.22 %
Jan 1, 2027 (e)
86.44 %
-100.00 %
-885.42 %
Jan 1, 2028 (e)
86.44 %
-100.00 %
-25.49 %

Perseus Proteomics Stock Revenue, EBIT, Earnings per Share

The Perseus Proteomics earnings per share therefore indicates how much revenue Perseus Proteomics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
5.81 JPY
-35.23 JPY
-35.36 JPY
Jan 1, 2022
6.12 JPY
-40.15 JPY
-50.94 JPY
Jan 1, 2023
8.01 JPY
-59.34 JPY
-66.93 JPY
Jan 1, 2024
8.52 JPY
-75.90 JPY
-93.69 JPY
Jan 1, 2025
8.44 JPY
-57.92 JPY
-63.41 JPY
Jan 1, 2026 (e)
77.35 JPY
-92.16 JPY
22.60 JPY
Jan 1, 2027 (e)
7.06 JPY
-8.41 JPY
-62.50 JPY
Jan 1, 2028 (e)
52.18 JPY
-62.16 JPY
-13.30 JPY

Perseus Proteomics business model & stock analysis

Perseus Proteomics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Perseus Proteomics historical P/E ratio, EBIT multiple, and P/S ratio

Perseus Proteomics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Perseus Proteomics shares outstanding

The number of shares of Perseus Proteomics was 14.27 M in 2025. This indicates how many shares Perseus Proteomics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
11.69 M Stocks
Jan 1, 2022
11.76 M Stocks
Jan 1, 2023
11.76 M Stocks
Jan 1, 2024
11.79 M Stocks
Jan 1, 2025
14.27 M Stocks
Jan 1, 2026 (e)
14.27 M Stocks
Jan 1, 2027 (e)
14.27 M Stocks
Jan 1, 2028 (e)
14.27 M Stocks

Current Perseus Proteomics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
765.00
Last Price
145.00
Currency
JPY
12M Return Potential
427.59 %
LTM Return
0 %

Perseus Proteomics shareholder structure

% Name
6.27750%
Nomura Securities Co., Ltd.
Nomura Securities Co., Ltd.
0.43118%
Macquarie Group Limited
Macquarie Group Limited

Perseus Proteomics Beneficial Ownership Filings (SEC 13D/G)

Free Float
90.1%
Float Shares
-
Shares Outstanding
-

Perseus Proteomics Executives and Management Board

9 members · avg. age 63 · 0 % women

Management

TY

Mr. Takuya Yokokawa (59)

President, Chief Executive Officer, Executive Officer, Representative Director · since 2018

–
SS

Mr. Shinichi Suzukawa (67)

Executive Officer, Director of Administration, Director · since 2020

–
SH

Mr. Shinji Hagiwara (58)

Executive Officer, Director of Research and Development, Director of Business Development, Director · since 2023

–
TM

Mr. Tadashi Matsuura (64)

Executive Officer · since 2019

–

Board of Directors

NH

Mr. Nobuo Hanai (70)

Independent Director

–
TH

Mr. Tadashi Horiuchi (76)

Independent Director

–
KK

Mr. Kinichiro Kominami (56)

Independent Director

–
TN

Mr. Tatsuya Nagase (66)

Independent Director

–
TO

Mr. Takashi Ohno (53)

Independent Director

–

Frequently asked questions about Perseus Proteomics

Analysts currently set an average price target of 765.00 JPY for the Perseus Proteomics stock (median: 765.00 JPY), implying +427.6 % versus the latest price. The consensus is based on 5 analyst ratings.

Perseus Proteomics Analyst Price Targets 2026

5 analysts currently rate the Perseus Proteomics stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Perseus Proteomics to generate revenue of 1.32 B JPY and earnings per share of 26.93 JPY.

Perseus Proteomics Analyst Price Targets 2026

Converted at the current exchange rate, the Perseus Proteomics share trades at 0.80 EUR (147.00 JPY).

No history available for Perseus Proteomics.

The expected revenue of Perseus Proteomics is 1.32 B JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Perseus Proteomics is 384.20 M JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Perseus Proteomics is currently 5.46. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Perseus Proteomics stock.

The price-to-sales ratio (P/S) of Perseus Proteomics is currently 1.60. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Perseus Proteomics stock.

The Eulerpool Quality Score for Perseus Proteomics is 3/10.

The ISIN of Perseus Proteomics is JP3836800007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Perseus Proteomics is 4882.T. The ticker symbol is used to trade Perseus Proteomics shares on the stock exchange.

Perseus Proteomics paid dividends every year for the past 0 years.

Perseus Proteomics is assigned to the 'Health' sector.

The dividends of Perseus Proteomics are distributed in JPY.

All fundamentals and in-depth analysis of Perseus Proteomics

Our stock analysis for Perseus Proteomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Perseus Proteomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Perseus Proteomics Stock
Perseus Proteomics Revenue→
Perseus Proteomics Stock
Perseus Proteomics Net Income→
Perseus Proteomics Stock
Perseus Proteomics P/E→
Perseus Proteomics Stock
Perseus Proteomics P/S→
Perseus Proteomics Stock
Perseus Proteomics EBIT→
Perseus Proteomics Stock
Perseus Proteomics Dividend→
Perseus Proteomics Stock
Perseus Proteomics Directors Dealings→
Perseus Proteomics Stock
Perseus Proteomics Stocks→
Perseus Proteomics Stock
Perseus Proteomics Market capitalization→
Perseus Proteomics Stock
Perseus Proteomics Debt→
Perseus Proteomics Stock
Perseus Proteomics Liabilities→
Perseus Proteomics Stock
Perseus Proteomics Equity→
Perseus Proteomics Stock
Perseus Proteomics AAQS→
Perseus Proteomics Stock
Perseus Proteomics Employees→
Perseus Proteomics Stock
Perseus Proteomics ROE→
Perseus Proteomics Stock
Perseus Proteomics ROA→
Perseus Proteomics Stock
Perseus Proteomics ROCE→
Perseus Proteomics Stock
Perseus Proteomics News→
Perseus Proteomics Stock
Perseus Proteomics Analyst Price Targets→

Health Stocks

PersonalisPerrigo CompanyPerspective TherapeuticsPerpetua Medical AB (publ)Pet Pharm Biotech CoPerfect Medical Industry CoPetros PharmaceuticalsPercheron TherapeuticsPetVivo HoldingsPeptronPfizerPeptonic MedicalAll Stocks A–Z →